The Hub for Disease-Specific Clinical Information

Recent News

Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
AACR 2019: Entinostat Plus Pembrolizumab for Melanoma After Immunotherapy
FDA Fast Track Designation: Tebentafusp in Metastatic Uveal Melanoma
Skin Cancer 2019: Can Microneedle Technology Improve Skin Cancer Treatment?
AACR 2019: Can B Cells Predict Response to Immunotherapy in Melanoma?
AACR 2019: Impact of Probiotics and Fiber on Gut Microbiome and Immunotherapy Response
Society of Behavioral Medicine Conference 2019: Web-Based Intervention for Melanoma Prevention
FDA Proposes Updated Requirements for Sunscreen Products
2019 AAD: Using Artificial Intelligence to Diagnose Skin Cancers
2019 ASCO-SITC Symposium: Predicting Outcomes With Immunotherapy for Melanoma
Does Superfamily of Motor Proteins Play a Role in Invasive Melanoma?
Treatment of Uveal Melanoma With Extract From Primrose Plant
FDA Approves Pembrolizumab in Adjuvant Treatment of Melanoma
Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity
MEK Inhibitor Under Study for Treatment of Brain Metastases From Melanoma
Predicting Which Melanoma Tumors Will Respond to Checkpoint Immunotherapy
Could the Protein Leucurogin Hinder the Growth of Melanoma Cells?
Vemurafenib Combination Therapy for BRAF -Mutated Melanoma
OpACIN Trial: Ipilimumab Plus Nivolumab in Stage III Melanoma
Do PPIs Affect the Efficacy of Immunotherapy in Metastatic Melanoma?
Radiolabeled Peptide Targeting Melanocortin-1 Receptor in Melanoma Imaging
Is Neoadjuvant Immunotherapy Effective in Treating High-Risk Melanoma?
Enhancing BH3 Mimetic Therapy for Melanoma
Immunotherapy Combination for Metastatic Uveal Melanoma
ESMO 2018: Adjuvant Pembrolizumab and Quality of Life in Patients With High-Risk Melanoma
ESMO 2018: 4-Year Follow-up Confirms Benefit of Nivolumab in Advanced Melanoma
ESMO 2018: Immunotherapy Triplet Therapy for BRAF-Mutated Melanoma
ASTRO 2018: Preclinical Findings on Novel Combination Therapy Against Melanoma
ESMO 2018: Dosing Regimens of Combination Nivolumab and Ipilimumab in Advanced Melanoma
Novel Models for Predicting Skin Cancer Risk

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.